Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K, Wa

Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K, Walczak H: Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 2005, 42:588–597.PubMedCrossRef 30. Moriai R, Asanuma K, Kobayashi D, Yajima T, Yagihashi A, Yamada M, Watanabe N: Quantitative analysis of the anti-apoptotic gene survivin expression in malignant

haematopoietic cells. Anticancer Res 2001, 21:595–600.PubMed 31. Yan XJ, Liang LZ, Zeng ZY, Shi Z, Fu LW: [Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel]. Ai Zheng 2006, 25:398–403.PubMed 32. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone

MG: Expression of the anti-apoptotic gene survivin correlates AZD6094 chemical structure with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002, 59:1406–1412.PubMedCrossRef 33. Azuma E, CFTRinh-172 ic50 Masuda S, Qi J, Kumamoto T, Hirayama M, Nagai M, Hiratake S, Umemoto M, Komada Y, Sakurai M: Cytotoxic T-lymphocytes recognizing P-glycoprotein in murine multidrug-resistant leukemias. Eur J Haematol 1997, 59:14–19.PubMedCrossRef 34. Arienti F, Gambacorti-Passerini C, Borin L, Rivoltini L, Orazi A, Pogliani EM, Corneo G, Parmiani G: Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules. Ann Oncol 1992, 3:155–162.PubMed 35. Margolin KA, Wright C, Forman SJ: Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells. Leukemia 1997, 11:723–728.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions QZ conceived of the study, and participated in its design and coordination and draft the manuscript. HZ conceived of the study, and participated in producing

CIK cells and helped to draft the manuscript. JL carried out the establishment of MDR cells, participated in the Observation of cell biological characteristics and helped to draft the manuscript. XH carried out the in vivo pharmacodynamics Idelalisib supplier and pathomorphology experiments in vitro anti-tumor studies. YL and LF participated in the design of the study and performed the statistical analysis. All authors read and approved the final manuscript.”
“Background Ataxia-telangiectasia (A-T) is an autosomal recessive disorder that affects many parts of the body and leads to increased risk of malignancy, including breast cancer [1–3]. A-T is caused by mutations in the ataxia telangiectasia-mutated (ATM) [4]. ATM, a member of the phosphatidylinositol 3-kinase-like BIBW2992 family, plays central roles in the repair of DNA double-strand breaks that was caused by a range of DNA-damaging agents such as ionizing radiation [5].

Comments are closed.